References
Li J, Thompson TD, Miller JW et al (2008) Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics 121:e1470–e1477
Pappo AS (1995) Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol 7:361–366
Parham DM (2001) Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 14:506–514
Skapek SX, Anderson J, Barr FG et al (2013) PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer 60:1411–1417
Arndt CA, Stoner JA, Hawkins DS et al (2009) Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol 27:5182–5188
Walterhouse DO, Pappo AS, Meza JL et al (2014) Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 32:3547–3552
Oberlin O, Rey A, Lyden E et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26:2384–2389
Klem ML, Grewal RK, Wexler LH et al (2007) PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 29:9–14
Eaton BR, McDonald MW, Kim S et al (2013) Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival. Cancer 119:1578–1585
Chen C, Shu HK, Goldwein JW et al (2003) Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 55:1294–1299
Ermoian RP, Breneman JC, Walterhouse DO et al (2016) Is 45 Gy a sufficient radiation therapy dose for unresected orbital embryonal rhabdomyosarcoma ? A report from the Soft Tissue Sarcoma Committee of the children’s oncology group. Int J Radiat Oncol Biol Phys 96(suppl 2):E548
Neville HL, Andrassy RJ, Lobe TE et al (2000) Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg 35:317–321
Wiener ES, Anderson JR, Ojimba JI et al (2001) Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 10:146–152
Casey DL, Wexler LH, LaQuaglia MP et al (2014) Patterns of failure for rhabdomyosarcoma of the perineal and perianal region. Int J Radiat Oncol Biol Phys 89:82–87
Blakely ML, Andrassy RJ, Raney RB et al (2003) Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. J Pediatr Surg 38:347–353
Lawrence W Jr, Anderson JR, Gehan EA et al (1997) Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Study Group Pediatric Oncology Group. Cancer 80:1165–1170
Walterhouse DO, Meza JL, Breneman JC et al (2011) Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children’s Oncology Group. Pediatr Blood Cancer 57:76–83
Ladra MM, Edgington SK, Mahajan A et al (2014) A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother Oncol 113:77–83
Cotter SE, Herrup DA, Friedmann A et al (2011) Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 81:1367–1373
Yock T, Schneider R, Friedmann A et al (2005) Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 63:1161–1168
Childs SK, Kozak KR, Friedmann AM et al (2012) Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 82:635–642
Ladra MM, Szymonifka JD, Mahajan A et al (2014) Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol 32:3762–3770
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Ladra, M., Marcus, K.J., Yock, T. (2019). Rhabdomyosarcoma. In: Terezakis, S., MacDonald, S. (eds) Target Volume Delineation for Pediatric Cancers. Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-69140-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-69140-4_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-69139-8
Online ISBN: 978-3-319-69140-4
eBook Packages: MedicineMedicine (R0)